Australian scientists believe they may be able to use a common cold-producingvirus to successfully treat breast cancer patients, in a way that is much lessdebilitating than chemotherapy.
AstraZeneca (NYSE: AZN) announced the commencement of a new Phase III study of its new investigational once-daily orally administered drug, vandetanib (ZACTIMA(R), ZD6474).
Women who regularly engage in strenuous physical activity may have a lower risk of developing both invasive breast cancer and in situ (early-stage) breast cancer than women who do not, according to a report in the Feb. 26 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
Significant findings have emerged from the California Teachers Study (CTS) that suggest long-term recreational physical activity plays a protective role against invasive and in situ breast cancer.
The future of cancer detection and treatment may be in gold nanoparticles ? tiny pieces of gold so small they cannot be seen by the naked eye.
Cancer cells differ from normal cells in, among other things, the way they divide. When a normal cell complies with a signal telling it to divide, it also begins to activate a “braking system” that eventually stops cell division and returns the cell to a resting state.
Boston-Androgen deprivation therapy – one of the most common treatments for prostate cancer – may increase the risk of death from heart disease in patients over age 65, according to a new study by researchers at Dana-Farber Cancer Institute, Brigham and Women’s Hospital and other institutions.
Cell Therapeutics, Inc. (CTI) announced preliminary results from a investigator-sponsored phase II study of XYOTAX(TM) (paclitaxel poliglumex) in patients with androgen independent prostate cancer, the majority of whom had failed prior treatment with taxane chemotherapy.
AstraZeneca announced the commencement of a new Phase III study of its new investigational once-daily orally administered drug, vandetanib (ZACTIMA(R), ZD6474).
Dr. Vafa Shahabi and her research team at Advaxis have designed several new strains of the Listeria bacteria that are programmed to kill off specific cancers.